Emami Sahar Sarmasti, Nekouian Reza, Akbari Abolfazl, Faraji Amirhossein, Abbasi Vida, Agah Shahram
Department of Medical Biotechnology, School of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran.
Department of Medical Biotechnology, School of Allied Medicine; Pediatric Growth and Development Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran.
J Cancer Res Ther. 2019 Jan-Mar;15(1):115-119. doi: 10.4103/jcrt.JCRT_592_17.
Gastric cancer is responsible for a large number of death worldwide and its high death rate is associated with a lack of noninvasive tools in GC diagnosis. MicroRNAs (miRNAs), as gene regulators, were shown to dysregulate in different types of cancer. Moreover, it is proven that miRNAs are stable in serum/plasma, so they can be used as a potential noninvasive marker in GC diagnosis. The objective of this study is to investigate the plasma miRNA expression in GC samples compared to controls as a potential biomarker in cancer diagnosis.
Expression levels of miR-21 and miR-222 were assessed using quantitative real-time polymerase chain reaction in plasma of 30 GC patients and 30 healthy controls. Diagnostic value of selected miRNAs was evaluated using receiver operating characteristic curve. Target prediction was done using bioinformatics tools to investigate the signaling pathways and function of the selected miRNAs.
Our results demonstrated that the expression levels of miR-21 and miR-222 were significantly higher in GC plasma than in the controls (P < 0.0001, P = 0.043). The sensitivity and specificity for miR-21 and in plasma were 86.7% and 72.2% and for miR-222 were 62.5% and 56.2%, respectively. Bioinformatics analysis revealed that most target genes of miR-21 and miR-222 are involved in cancer-related signaling pathway such as tumor initiation and progression.
Our results indicated that miR-21 and miR-222 in plasma samples can be served as a potential noninvasive tool in GC detection. Furthermore, the miRNA target prediction manifested that miR-21 and miR-222 involve in key processes associated with GC initiation and development.
胃癌在全球导致大量死亡，其高死亡率与胃癌诊断中缺乏非侵入性工具有关。微小RNA（miRNA）作为基因调节因子，在不同类型癌症中显示出失调。此外，已证实miRNA在血清/血浆中稳定，因此它们可作为胃癌诊断中潜在的非侵入性标志物。本研究的目的是调查胃癌样本与对照相比血浆中miRNA的表达情况，作为癌症诊断中的潜在生物标志物。
使用定量实时聚合酶链反应评估30例胃癌患者和30例健康对照血浆中miR-21和miR-222的表达水平。使用受试者工作特征曲线评估所选miRNA的诊断价值。使用生物信息学工具进行靶标预测，以研究所选miRNA的信号通路和功能。
我们的结果表明，胃癌患者血浆中miR-21和miR-222的表达水平显著高于对照组（P < 0.0001，P = 0.043）。血浆中miR-21的敏感性和特异性分别为86.7%和72.2%，miR-222的敏感性和特异性分别为62.5%和56.2%。生物信息学分析显示，miR-21和miR-222的大多数靶基因参与癌症相关信号通路，如肿瘤起始和进展。
我们的结果表明，血浆样本中的miR-21和miR-222可作为胃癌检测中潜在的非侵入性工具。此外，miRNA靶标预测表明，miR-21和miR-222参与与胃癌起始和发展相关的关键过程。
